MA44234B1 - Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 - Google Patents

Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3

Info

Publication number
MA44234B1
MA44234B1 MA44234A MA44234A MA44234B1 MA 44234 B1 MA44234 B1 MA 44234B1 MA 44234 A MA44234 A MA 44234A MA 44234 A MA44234 A MA 44234A MA 44234 B1 MA44234 B1 MA 44234B1
Authority
MA
Morocco
Prior art keywords
methods
treating
angptl3
administration
preventing atherosclerosis
Prior art date
Application number
MA44234A
Other languages
English (en)
Other versions
MA44234A (fr
Inventor
Jesper Gromada
Andrew J Murphy
Viktoria Gusarova
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA44234A publication Critical patent/MA44234A/fr
Publication of MA44234B1 publication Critical patent/MA44234B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés et des compositions permettant de traiter ou de prévenir l'athérosclérose chez un sujet. Les procédés de la présente invention comprennent l'administration d'un inhibiteur de la protéine du type angiopoïétine 3 (angptl3) à un sujet atteint d'athérosclérose ou susceptible de développer une athérosclérose. Selon certains modes de réalisation, l'inhibiteur de l'angptl3 est un anticorps ou un fragment de liaison à antigène correspondant qui se lie spécifiquement à l'angptl3.
MA44234A 2016-02-17 2017-02-13 Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 MA44234B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296110P 2016-02-17 2016-02-17
PCT/US2017/017640 WO2017142832A1 (fr) 2016-02-17 2017-02-13 Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3

Publications (2)

Publication Number Publication Date
MA44234A MA44234A (fr) 2018-12-26
MA44234B1 true MA44234B1 (fr) 2023-10-31

Family

ID=58108756

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44234A MA44234B1 (fr) 2016-02-17 2017-02-13 Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3

Country Status (25)

Country Link
US (3) US20170233466A1 (fr)
EP (2) EP4234013A3 (fr)
JP (3) JP7648335B2 (fr)
KR (1) KR102860143B1 (fr)
CN (1) CN108697797A (fr)
AU (1) AU2017219602C1 (fr)
CA (1) CA3014928A1 (fr)
DK (1) DK3416684T5 (fr)
EA (1) EA201891853A1 (fr)
ES (1) ES2951262T3 (fr)
FI (1) FI3416684T3 (fr)
HR (1) HRP20230992T1 (fr)
HU (1) HUE062709T2 (fr)
IL (1) IL260931B2 (fr)
LT (1) LT3416684T (fr)
MA (1) MA44234B1 (fr)
MD (1) MD3416684T2 (fr)
MX (1) MX2018009680A (fr)
PL (1) PL3416684T3 (fr)
PT (1) PT3416684T (fr)
RS (1) RS64476B1 (fr)
SI (1) SI3416684T1 (fr)
SM (1) SMT202300219T1 (fr)
WO (1) WO2017142832A1 (fr)
ZA (1) ZA201805058B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
CN109096369B (zh) * 2018-09-10 2020-07-07 云南民族大学 一种特异性检测铜离子和硫离子的多肽、化学荧光传感器及其制备方法与应用
EP3880819A2 (fr) * 2018-11-13 2021-09-22 Lipigon Pharmaceuticals AB Oligonucléotides d'angptl4 influençant la régulation du métabolisme des acides gras
WO2020099525A2 (fr) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Oligonucléotides influençant la régulation du métabolisme des acides gras
WO2020099482A2 (fr) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Oligonucléotides d'angptl3 influençant la régulation du métabolisme des acides gras
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
CN112062844B (zh) * 2019-06-10 2022-07-19 山东博安生物技术股份有限公司 抗angptl3抗体及其用途
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
CN110596399B (zh) * 2019-08-29 2022-07-22 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CA3166346A1 (fr) * 2020-01-22 2021-07-29 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-angptl3 et son utilisation
IL316249A (en) * 2022-05-02 2024-12-01 Novo Nordisk As Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN115947779B (zh) * 2022-08-10 2025-04-25 武汉安砥生物科技有限公司 针对人血管生成素样蛋白3的免疫原性肽段及其载体疫苗和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) * 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
EP1151092B1 (fr) 1999-02-12 2008-12-31 President And Fellows Of Harvard College Inhibition de la formation des lesions atherosclereuses avec des acides nucléiques antisens d'afabp
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2008073300A2 (fr) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Anticorps monoclonaux dirigés contre angptl3
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2398476B1 (fr) 2009-02-23 2018-02-07 Nanorx, Inc. Nanoparticules de policosanol
CN102753186B (zh) * 2010-01-08 2016-09-14 Isis制药公司 血管生成素样3表达的调节
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US20160002315A1 (en) 2013-03-14 2016-01-07 Uab Research Foundation Apolipoprotein mimetics and uses thereof
US10494442B2 (en) * 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
PT3087183T (pt) * 2013-12-24 2020-10-08 Ionis Pharmaceuticals Inc Modulação da expressão da proteína relacionada com angiopoietina 3
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途

Also Published As

Publication number Publication date
JP2019509271A (ja) 2019-04-04
IL260931A (en) 2018-09-20
JP7648335B2 (ja) 2025-03-18
EP3416684A1 (fr) 2018-12-26
CN108697797A (zh) 2018-10-23
MA44234A (fr) 2018-12-26
JP2022177107A (ja) 2022-11-30
LT3416684T (lt) 2023-07-25
PL3416684T3 (pl) 2023-11-06
ZA201805058B (en) 2019-05-29
DK3416684T5 (da) 2024-09-16
SMT202300219T1 (it) 2023-09-06
JP2024161504A (ja) 2024-11-19
HRP20230992T1 (hr) 2023-12-08
HUE062709T2 (hu) 2023-11-28
US20170233466A1 (en) 2017-08-17
EP4234013A3 (fr) 2023-11-08
FI3416684T3 (fi) 2023-07-31
KR102860143B1 (ko) 2025-09-16
AU2017219602B2 (en) 2023-10-12
AU2017219602A1 (en) 2018-08-23
AU2017219602C1 (en) 2024-05-09
EP4234013A2 (fr) 2023-08-30
US20200079841A1 (en) 2020-03-12
IL260931B2 (en) 2024-09-01
DK3416684T3 (da) 2023-07-31
MX2018009680A (es) 2018-09-10
PT3416684T (pt) 2023-07-04
IL260931B1 (en) 2024-05-01
EP3416684B1 (fr) 2023-06-21
US20220089711A1 (en) 2022-03-24
EA201891853A1 (ru) 2019-01-31
KR20180108840A (ko) 2018-10-04
RS64476B1 (sr) 2023-09-29
SI3416684T1 (sl) 2023-08-31
CA3014928A1 (fr) 2017-08-24
MD3416684T2 (ro) 2023-10-31
ES2951262T3 (es) 2023-10-19
WO2017142832A1 (fr) 2017-08-24

Similar Documents

Publication Publication Date Title
MA44234B1 (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
EA201592267A1 (ru) Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
EP3746119A4 (fr) Procédés de traitement du cancer ou d'une infection à l'aide d'une combinaison d'un anticorps anti-pd -1, d'un anticorps anti-lag3 et d'un anticorps anti-tigit
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MX2019010408A (es) Formulacion de anticuerpo monoclonal anti-vrs.
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
NO20054292L (no) Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette
MA54975A1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
BR112018000771A2 (pt) anticorpos que se ligam à sortilina e inibem a ligação de progranulina, composições farmacêuticas, preparações dos mesmos, uso de anticorpos, kit e método de prevenção ou tratamento de uma doença associada a níveis diminuídos de pgrn
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
GEAP202515689A (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MA34135B1 (fr) Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique
CL2020001307A1 (es) Formulación.
CR20230528A (es) Anticuerpo anti componente del complemento 1s (c1s)
BR112023002234A2 (pt) Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
FR3082427B1 (fr) Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x